# Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

> **NCT00219765** · PHASE1,PHASE2 · TERMINATED · sponsor: **Poitiers University Hospital** · enrollment: 30 (—)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib mesylate 600 mg
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicine

## Key facts

- **NCT ID:** NCT00219765
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 30 (—)
- **Last updated:** 2005-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219765, "Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00219765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*